LOS ANGELES--(BUSINESS WIRE)--The Wagner Firm announces that it is investigating the board of directors of the DepoMed, Inc. (“DepoMed”) (NASDAQ:DEPO) concerning possible breaches of fiduciary duty. Specifically, the investigation relates to whether DepoMed’s board of directors has failed to adequately consider the recent acquisition proposition from Horizon Pharma PLC. Further, the investigation concerns whether the board of directors has breached their fiduciary duty to shareholders by implementing a poison-pill plan and amending DepoMed’s bylaws.
If you are a shareholder of DepoMed and wish to learn more about this investigation, please contact Avi Wagner, Esquire, of The Wagner Firm, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 491-7949, by e-mail at email@example.com, or visit our website at http://thewagnerfirm.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.